![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bausch and Lomb Corporation | TSX:BLCO | Toronto | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.23 | 1.16% | 20.03 | 19.50 | 20.20 | 20.03 | 19.95 | 19.95 | 630 | 21:00:01 |
Four Poster Presentations Will Include Research on Company's Latest Solution That Provides More Moisture on Lenses for Patients1
Bausch + Lomb Will Also Sponsor Nine Educational Events
VAUGHAN, Ontario, Oct. 18, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that four scientific poster presentations will feature research evaluating Biotrue Hydration Plus Multi-Purpose Solution during the annual meeting of the American Academy of Optometry (AAO), which will take place in San Diego from Oct. 26-29, 2022.
Additionally, Bausch + Lomb will sponsor nine educational events that will include discussion of: Biotrue Hydration Plus; the Bi-Elevation™ technique using Bausch + Lomb's Zenlens® scleral lenses; Revive™ custom soft contact lenses; the National Eye Institute's (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2); several of the company's pharmaceutical products; and dry eye disease (DED), one of the most common ocular surface disorders that affects approximately 18 million Americans1,2.
"Bausch + Lomb is committed to conducting research that further demonstrates the clinical benefits of our current portfolio, including our Biotrue Hydration Plus Multi-Purpose Solution, which provides more moisture on lenses for 12 hours – up to a full day of wear – compared to our original Biotrue solution3," said Joseph C. Papa, CEO, Bausch + Lomb. "We look forward to connecting with eye care professionals at the AAO meeting to present these data and host a number of educational programs that are designed to help meet the needs of our customers and, ultimately, their patients."
The complete list of scientific poster presentations, as well as details for the sponsored education events is as follows:
Poster Presentations
Featured Education Events
Important Safety Information for LOTEMAX SM
INDICATION
LOTEMAX SM (loteprednol etabonate ophthalmic gel) 0.38% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.
IMPORTANT SAFETY INFORMATION
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information for LOTEMAX SM.
Important Safety Information for VYZULTA
INDICATION
VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
IMPORTANT SAFETY INFORMATION
Please click here for full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
About Biotrue Hydration Plus Multi-Purpose Solution
Biotrue Hydration Plus Multi-Purpose Solution contains a combination of ingredients inspired by the Tear Film and Ocular Surface Society's DEWS II report. The ingredients include potassium, an electrolyte, which is found naturally in tears and plays an important role in ocular surface homeostasis, as well as an antioxidant, which protects hyaluronan (HA) against free radicals and also helps maintain ocular surface homeostasis. The solution also contains 25% more4 HA, a moisturizer found naturally in tears, to help keep more moisture3 on contact lenses. For more information, visit www.biotrue.com.
About Zenlens Scleral Lenses and Revive Custom Contact Lenses
Please see www.bauschsvp.com for important safety information for gas permeable and customizable contact lenses.
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.
Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb's filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch + Lomb, including but not limited to its project development timelines, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
References
®/TM are trademarks of Bausch & Lomb Incorporated or its affiliates. Any other product/brand names and/or logos are trademarks of the respective owners. © 2022 Bausch & Lomb Incorporated or its affiliates.ABT.0080.USA.22
Investor Contacts: | Media Contacts: |
Arthur Shannon | Lainie Keller |
arthur.shannon@bausch.com | lainie.keller@bausch.com |
(908) 927-1198 | |
Allison Ryan | |
allison.ryan@bausch.com | Kristy Marks |
(877) 354-3705 (toll free) | kristy.marks@bausch.com |
(908) 927-0735 | (908) 927-0683 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch--lomb-announces-presentation-of-scientific-data-and-analyses-evaluating-biotrue-hydration-plus-multi-purpose-solution-at-american-academy-of-optometry-annual-meeting-301651381.html
SOURCE Bausch + Lomb Corporation
Copyright 2022 PR Newswire
1 Year Bausch and Lomb Chart |
1 Month Bausch and Lomb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions